



## DAFTAR PUSTAKA

1. Xu L, Fang J, Weng W, Huang K, Zhang Y. Autoimmune Hemolytic Anemia in Patients with  $\beta$ -Thalassemia Major. *Pediatr Hematol Oncol*. 2012;(107):235–40.
2. Khaled M, Ouederni M, Sahli N, Dhouib N, Ben A, Rekaya S, et al. Predictors of autoimmune hemolytic anemia in beta-thalassemia patients with underlying red blood cells autoantibodies. *Blood Cells, Mol Dis* [Internet]. 2019;79(June):102342. Available from: <https://doi.org/10.1016/j.bcmd.2019.102342>
3. Aji DN, Silman C, Aryudi C, Andalia D, Anak K. Faktor–Faktor yang Berhubungan dengan Kualitas Hidup Pasien Talassemia Mayor di Pusat Talassemia Departemen Ilmu Kesehatan Anak RSCM. 2009;11(2):85–9.
4. Modell B, Darlison M. Global Epidemiology of haemoglobin disorders and derived service indicators. *Bull World Health Organ*. 2008;036673(June 2007).
5. Menteri Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1/2018 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Talasemia. 2018;1–90.
6. Rosita L. Surveilans Penderita Talasemia di RSUP Dr . Sardjito Yogyakarta Tahun 2004. *Mutiara Med*. 2007;7(2):109–20.
7. Wahidiyat PA, Sari TT, Rahmartani LD, Setianingsih I, Iskandar SD, Pratanata AM, et al. An insight into Indonesian current thalassaemia care and challenges. *ISBT Sci Ser*. 2020;15(3):334–41.
8. Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, et al. Relationship among chelator adherence, change in chelators, and quality of life in Talassemia. *Qual Life Res*. 2014;23(8):2277–88.
9. Aladjidi N, Leverger G, Leblanc T, Picat MQ, Michel G, Bertrand Y, et al. New insights into childhood autoimmune hemolytic anemia: A French national observational study of 265 children. *Haematologica*. 2011;96(5):655–63.
10. Chi X, Wang W, Huang C, Wu M, Zhang L, Li J, et al. Risk factors for mortality in patients with anti-NMDA receptor encephalitis. *Acta Neurol Scand*. 2017;136(4):298–304.
11. Caplan A, Fett N, Rosenbach M, Werth VP, Micheletti RG. Prevention and management of glucocorticoid-induced side effects : A comprehensive review. *J Am Dermatology* [Internet]. 2020;76(2):201–7. Available from: <http://dx.doi.org/10.1016/j.jaad.2016.02.1241>
12. Oray M, Abusamra K, Ebrahimiadib N, Meese H. Long-term side effects of



- glucocorticoids. Expert Opin Drug Saf. 2016;(January).
13. Margolin L, Cope DK, Bakst-sisser R, Greenspan J. The Steroid Withdrawal Syndrome : A Review of the Implications , Etiology , and Treatments. J Pain Symptom Manage. 2007;33(2):224–8.
  14. El Danasoury AS, Eissa DG, Abdo RM, Elalfy MS. Red blood cell alloimmunization in transfusion-dependent Egyptian patients with thalassemia in a limited donor exposure program. Transfusion. 2012;52(1):43–7.
  15. Fibach E, Rachmilewitz EA. Pathophysiology and treatment of patients with beta-thalassemia - an update. F1000Research. 2017;6(0).
  16. Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the  $\beta$ -thalassemias. Cold Spring Harb Perspect Med. 2012;2(12):1–13.
  17. Origa R.  $\beta$  -Thalassemia. Genet Med. 2017;19(6):609–19.
  18. Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Splenectomy in  $\beta$ -thalassaemia. 2008 [cited 2019 Aug 18]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK173963/>
  19. Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Endocrine Complications In Thalassaemia Major. 2008 [cited 2019 Aug 18]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK173978/#S126>
  20. Tantiworawit A, Tapanya S, Phrommintikul A, Saekho S, Rattarittamrong E, Norasetthada L, et al. Prevalence and Risk Factors for Cardiac Iron Overload and Cardiovascular Complications among Patients with Thalassemia in Northern Thailand. Southeast Asian J Trop Med Public Heal. 2016;47(6):1335–42.
  21. Yasmeen H. Epidemiology and risk factors of transfusion transmitted infections in thalassemia major: a multicenter study in Pakistan. Hematol Transfus Cell Ther [Internet]. 2019;(x x):1–8. Available from: <https://doi.org/10.1016/j.htct.2019.03.008>
  22. Indrasari N, Timan I, Amalia P. Perbedaan Kolagen IV di Kerusakan Hati dan Infeksi Hepatitis C Pasien Talasemia dengan Kelebihan Zat Besi. Indones J Clin Pathol Med Lab. 2015;22(1).
  23. Damardjati F, Oswari H. Hepatitis C pada Thalassemia mayor: pengaruh Iron Overload pada perjalanan penyakit. Sari Pediatr. 2003;5(1):16–20.
  24. Vichinsky E, Neumayr L, Trimble S, Giardina PJ, Cohen AR, Coates T, et al. Transfusion Complications in Thalassemia Patients: A Report from the Centers for Disease Control and Prevention ( CDC ). Transfusion. 2015;54(4):1–20.
  25. Dhawan HK, Kumawat V, Marwaha N, Sharma RR, Sachdev S, Bansal D, et al.



- Alloimmunization and autoimmunization in transfusion dependent thalassemia major patients : Study on 319 patients. *Asian J Transfus Sci.* 2014;8(2).
26. Rajaeefard A, Hajipour M, Tabatabaee HR, Hassanzadeh J, Rezaeian S, Moradi Z, et al. Analysis of survival data in thalassemia patients in Shiraz, Iran. *Epidemiol Health.* 2015;37:e2015031.
  27. Hill QA, Stamps R, Massey E, Grainger JD, Provan D, Hill A. The diagnosis and management of primary autoimmune haemolytic anaemia. *Br J Haematol.* 2017;176(3):395–411.
  28. Warady BA, Chadha V. Chronic kidney disease in children: The global perspective. *Pediatr Nephrol.* 2007;22(12):1999–2009.
  29. Thabet AF, Faisal M. Pulse Cyclophosphamide Therapy in Refractory Warm Autoimmune Hemolytic Anemia: A New Perspective. *Indian J Hematol Blood Transfus.* 2014;30(4):313–8.
  30. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. *Haematologica.* 2014;99(10):1547–54.
  31. Dussadee K, Taka O, Thedsawad A, Wanachiwanawin W. Incidence and risk factors of relapses in idiopathic autoimmune hemolytic anemia. *J Med Assoc Thail.* 2010;93(SUPPL 1):165–70.
  32. Seema G, Ruhi M. Red Cell Allo-Immunization in Thalassemia Patients. *J Evol Med Dent Sci.* 2016;5(42):2681–4.
  33. Dhirar N, Khandekar J, Bachani D, Mahto D. Thalassemia Major: how do we improve quality of life? *Springerplus.* 2016;5(1):0–5.
  34. Thiyagarajan A, Bagavandas M, Kosalram K. Assessing the role of family well-being on the quality of life of Indian children with thalassemia. *BMC Pediatr.* 2019;19(1):1–7.
  35. Evers D, van der Bom JG, Tijmensen J, Middelburg RA, de Haas M, Zalpuri S, et al. Red cell alloimmunisation in patients with different types of infections. *Br J Haematol.* 2016;175(5):956–66.
  36. Weli M, Ben Hlima A, Belhadj R, Maalej B, Elleuch A, Mekki N, et al. Diagnosis and management of autoimmune hemolytic anemia in children. *Transfus Clin Biol* [Internet]. 2020;27(2):61–4. Available from: <https://doi.org/10.1016/j.tracli.2020.03.003>
  37. Tangvarasittichai S. Impact of alloimmunization on transfusion-dependent patient. *Ann Adv Chem.* 2017;1(2):070–82.



38. Jain A, Agnihotri A, Marwaha N, Sharma RR. Direct antiglobulin test positivity in multi-transfused thalasseemics. *Asian J Transfus Sci.* 2016;10(2):161–3.
39. Franchini M, Forni GL, Marano G, Cruciani M, Mengoli C, Pinto V, et al. Red blood cell alloimmunisation in transfusion-dependent thalassaemia: A systematic review. *Blood Transfus.* 2019;17(1):4–15.
40. Saki F, Bahadori R, Kashkooli NM, Jazayeri A, Ghahremani N, Omrani GHR. Prevalence of metabolic syndrome in beta thalassemia major adolescents in southern Iran: a cross-sectional study. *Int J Diabetes Dev Ctries.* 2019;39(3):444–50.
41. Ayoub MD, Radi SA, Azab AM, Abulaban AA, Balkhoyor AH, Bedair SEW, et al. Quality of life among children with beta-thalassemia major treated in western Saudi Arabia. *Saudi Med J.* 2013;34(12):1281–6.
42. Hakeem GLA, Mousa SO, Moustafa AN, Mahgoob MH, Hassan EE. Health-related quality of life in pediatric and adolescent patients with transfusion-dependent  $\beta$ -thalassemia in upper Egypt (single center study). *Health Qual Life Outcomes.* 2018;16(1):1–9.
43. Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. *J Clin Oncol* [Internet]. 2017;35(18):2082–94. Available from: <http://ascopubs.org/doi/10.1200/JCO.2016.71.7017>  
<http://www.ncbi.nlm.nih.gov/pubmed/28459614>
44. Belsito A, Costa D, Signoriello S, Fiorito C, Tartaglione I, Casale M, et al. Clinical outcome of transfusions with extended red blood cell matching in  $\beta$ -thalassemia patients: A single-center experience. *Transfus Apher Sci* [Internet]. 2019;58(1):65–71. Available from: <https://doi.org/10.1016/j.transci.2018.11.006>
45. Jalali SF, Oodi A, Azarkeivan A, Gudarzi S, Amirizadeh N. Kidd Blood Group Genotyping for Thalassemia Patient in Iran. *Indian J Hematol Blood Transfus* [Internet]. 2020;36(3):550–5. Available from: <https://doi.org/10.1007/s12288-020-01283-y>
46. Mangwana S, Kacker A, N. S. Red cell alloimmunization in multi-transfused, oncology patients: Risks and management. *Glob J Transfus Med.* 2019;4(1):74.
47. Handa A, Kukar N, Maharishi R, Syal N, Arora H. Analysis of red cell alloimmunization in multi transfused patients at a Tertiary care teaching hospital. *J Fam Med Prim Care* [Internet]. 2020 [cited 2020 Nov 21];9(6):2907. Available from:



48. Aghamaleki MA, Tamaddoni A, Nesheli, Hajiahmadi M, Samakoush MA, Aghajanpour F. Pubertal status and its relation with serum ferritin level in thalassemia major patients. *Iran J Pediatr Hematol Oncol*. 2019;9(1):32–9.
49. Kontoghiorghes GJ, Kleanthous M, Kontoghiorghes CN. The history of deferiprone (L1) and the paradigm of the complete treatment of iron overload in thalassaemia. *Mediterr J Hematol Infect Dis*. 2020;11(1):1–17.